Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of AMG 420 in Relapsed/Refractory Multiple Myeloma
NCT02514239Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2015
- Primary completion
- Jul 2018
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of pacanalotamab in multiple myeloma (MM) (13 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose and Dose-limiting Toxicities. Started Jul 2015; status: completed.
02
Drugs
pacanalotamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02514239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514239.